Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.

Passero FC Jr, Grapsa D, Syrigos KN, Saif MW.

Expert Rev Anticancer Ther. 2016 Jul;16(7):697-703. doi: 10.1080/14737140.2016.1192471. Epub 2016 Jun 3. Review.

PMID:
27219482
2.

Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC.

Strimpakos AS, Banerji U, Thavasu P, Tsilimagou A, Psyrri A, Syrigos KN.

Oncology. 2015;89(1):53-9. doi: 10.1159/000371711. Epub 2015 Feb 28.

PMID:
25766505
3.

Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma.

Saif MW, Ledbetter L, Kaley K, Garcon MC, Rodriguez T, Syrigos KN.

Oncol Lett. 2014 Sep;8(3):1302-1306. Epub 2014 Jun 11.

4.

Targeted agents in treatment of neuroendocrine tumors of pancreas.

Karampelas IN, Syrigos KN, Saif MW.

JOP. 2014 Jul 28;15(4):351-3. doi: 10.6092/1590-8577/2694. Review.

5.

Elderly patients with pancreatic cancer.

Kougioumtzopoulou AS, Syrigos KN, Saif MW.

JOP. 2014 Jul 28;15(4):322-5. doi: 10.6092/1590-8577/2682.

6.

Quality of life in patients with pancreatic cancer.

Kiagia M, Syrigos KN, Saif MW.

JOP. 2014 Jul 28;15(4):317-8. doi: 10.6092/1590-8577/2679.

7.

First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.

Ramfidis VS, Psyrri A, Syrigos KN, Saif MW.

JOP. 2014 Jul 28;15(4):286-8. doi: 10.6092/1590-8577/2622.

8.

Mixed acinar-neuroendocrine carcinoma of the pancreas with neuroendocrine predominance.

Ogbonna OH, Garcon MC, Syrigos KN, Saif MW.

Case Rep Med. 2013;2013:705092. doi: 10.1155/2013/705092. Epub 2013 Nov 17.

9.

Epidemiology of active tuberculosis in lung cancer patients: a systematic review.

Christopoulos A, Saif MW, Sarris EG, Syrigos KN.

Clin Respir J. 2014 Oct;8(4):375-81. doi: 10.1111/crj.12094. Epub 2014 Mar 5. Review.

PMID:
24345074
10.

Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma.

Mohammad MM, Syrigos KN, Saif MW.

Case Rep Dermatol Med. 2013;2013:825717. doi: 10.1155/2013/825717. Epub 2013 Sep 1.

11.

Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.

Sarris EG, Syrigos KN, Saif MW.

JOP. 2013 Jul 10;14(4):395-400. doi: 10.6092/1590-8577/1654.

12.

Update on novel therapies for pancreatic neuroendocrine tumors: 2013.

Dimou A, Syrigos KN, Saif MW.

JOP. 2013 Jul 10;14(4):377-80. doi: 10.6092/1590-8577/1647.

13.

Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications.

Strimpakos AS, Syrigos KN, Saif MW.

JOP. 2013 Jul 10;14(4):359-62. doi: 10.6092/1590-8577/1662.

14.

New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma.

Ramfidis VS, Syrigos KN, Saif MW.

JOP. 2013 Jul 10;14(4):344-6. doi: 10.6092/1590-8577/1650.

15.

Pancreatic cancer: what about screening and detection?

Konstantinou F, Syrigos KN, Saif MW.

JOP. 2013 Jul 10;14(4):312-5. doi: 10.6092/1590-8577/1645.

16.

Nutrition habits, physical activity, and lung cancer: an authoritative review.

Koutsokera A, Kiagia M, Saif MW, Souliotis K, Syrigos KN.

Clin Lung Cancer. 2013 Jul;14(4):342-50. doi: 10.1016/j.cllc.2012.12.002. Epub 2013 Jan 31. Review.

PMID:
23375445
17.

Dysfunctional remembered parenting in oncology outpatients affects psychological distress symptoms in a gender-specific manner.

Kouzoupis AV, Lyrakos D, Kokras N, Panagiotarakou M, Syrigos KN, Papadimitriou GN.

Stress Health. 2012 Dec;28(5):381-8. doi: 10.1002/smi.2460. Epub 2012 Oct 1.

PMID:
23023836
18.

Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?

Ramfidis VS, Strimpakos AS, Syrigos KN, Saif MW.

JOP. 2012 Jul 10;13(4):358-60. doi: 10.6092/1590-8577/948.

19.

Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer.

Strimpakos AS, Syrigos KN, Saif MW.

JOP. 2012 Jul 10;13(4):345-8. doi: 10.6092/1590-8577/947.

20.

Clinical and laboratory biomarkers in the management of pancreatic adenocarcinoma.

Strimpakos AS, Syrigos KN, Saif MW.

JOP. 2012 Jul 10;13(4):338-41. doi: 10.6092/1590-8577/943.

Supplemental Content

Loading ...
Support Center